Sei Investments Co. Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sei Investments Co. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,432 shares of the biopharmaceutical company's stock after selling 3,371 shares during the quarter. Sei Investments Co.'s holdings in Regeneron Pharmaceuticals were worth $18,825,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter worth about $26,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. Finally, Private Wealth Management Group LLC grew its position in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 39 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 2.7 %

Shares of REGN stock traded down $17.23 during trading hours on Tuesday, reaching $617.00. 1,059,572 shares of the company's stock were exchanged, compared to its average volume of 677,760. Regeneron Pharmaceuticals, Inc. has a 1 year low of $612.28 and a 1 year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market cap of $67.45 billion, a PE ratio of 16.12, a PEG ratio of 2.34 and a beta of 0.27. The stock's fifty day moving average price is $681.52 and its two-hundred day moving average price is $788.06.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $11.86 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.57%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Analyst Ratings Changes

REGN has been the subject of a number of recent analyst reports. Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Citigroup lowered their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Finally, BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.